Drug intelligence / Profile preview

ALTA-002

Development stage: Unknown
Lead developer: Tallac Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Systemic

Overview

ALTA-002 is a SIRPα-directed TLR9 agonist antibody conjugate designed to activate myeloid cells and promote anti-tumor immunity. It is being developed for the treatment of solid tumors and works by delivering a potent TLR9 agonist to myeloid cells via SIRPα and FcγR engagement, leading to robust cellular activation and cytokine induction. It enhances tumor regression when combined with anti-PD-1 therapy in preclinical models.

Other names: Anti-SIRPa antibody conjugated toll-like receptor 9 agonists

Targets

SIRPA (Signal-regulatory protein alpha)TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on ALTA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALTA-002.

Explore the full profile